Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus

Texto completo
Autor(es):
de Freitas, Natalia Lourenco [1] ; Deberaldini, Maria Gabriela [2, 3] ; Gomes, Diana [4] ; Pavan, Aline Renata [2, 3] ; Sousa, Angela [4] ; Dos Santos, Jean Leandro [3] ; Soares, Christiane P. [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Clin Anal, Araraquara, SP - Brazil
[2] Sao Paulo State Univ UNESP, Inst Chem, Araraquara, SP - Brazil
[3] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Drugs & Med Dept, Araraquara, SP - Brazil
[4] Univ Beira Interior, CICS UBI Hlth Sci Res Ctr, Covilha - Portugal
Número total de Afiliações: 4
Tipo de documento: Artigo de Revisão
Fonte: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY; v. 8, JAN 28 2021.
Citações Web of Science: 0
Resumo

The role of epigenetic modifications on the carcinogenesis process has received a lot of attention in the last years. Among those, histone acetylation is a process regulated by histone deacetylases (HDAC) and histone acetyltransferases (HAT), and it plays an important role in epigenetic regulation, allowing the control of the gene expression. HDAC inhibitors (HDACi) induce cancer cell cycle arrest, differentiation, and cell death and reduce angiogenesis and other cellular events. Human papillomaviruses (HPVs) are small, non-enveloped double-stranded DNA viruses. They are major human carcinogens, being intricately linked to the development of cancer in 4.5% of the patients diagnosed with cancer worldwide. Long-term infection of high-risk (HR) HPV types, mainly HPV16 and HPV18, is one of the major risk factors responsible for promoting cervical cancer development. In vitro and in vivo assays have demonstrated that HDACi could be a promising therapy to HPV-related cervical cancer. Regardless of some controversial studies, the therapy with HDACi could target several cellular targets which HR-HPV oncoproteins could be able to deregulate. This review article describes the role of HDACi as a possible intervention in cervical cancer treatment induced by HPV, highlighting the main advances reached in the last years and providing insights for further investigations regarding those agents against cervical cancer. (AU)

Processo FAPESP: 18/11079-0 - Síntese e atividade antituberculose de novos derivados N-óxidos planejados para o tratamento da tuberculose multirresistente
Beneficiário:Jean Leandro dos Santos
Modalidade de apoio: Auxílio à Pesquisa - Regular